The European Commission’s Pharmaceutical Sector Inquiry raised significant concerns regarding so-called “reverse payment” patent settlement agreements. In this article, CRA describes the types of information or economic evidence that might facilitate evaluation of the competitive aspects of these settlements. To read the article, click here:
CRA experts win prestigious 2026 Antitrust Writing Awards
The awards recognize outstanding scholarship and advocacy in antitrust law and economics. Christian Michel, a principal in the Antitrust & Competition...